NASDAQ$KIDS
OrthoPediatrics Corp · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
OrthoPediatrics reported a strong third quarter with record revenue and strategic acquisitions.
OrthoPediatrics Corp. reported a 39% increase in revenue for the third quarter of 2022, reaching $35.0 million compared to $25.1 million in the same period last year. This growth includes contributions from recent acquisitions MD Ortho and Pega Medical. The company's net income for the quarter was $18.5 million, a significant improvement from the net loss of $2.2 million in the third quarter of 2021.
- Total revenue reached $35.0 million, a 39% increase year-over-year.
- Worldwide Trauma & Deformity revenue grew by 42%, Scoliosis revenue increased by 37%, and Sports Medicine/Other revenue grew by 8%.
- The company completed the acquisition of Pega Medical and a follow-on public offering, raising $144 million.
- Net income for the third quarter of 2022 was $18.5 million, compared to a net loss of $2.2 million for the same period last year.
Headline financials
Revenue & EPS history
OrthoPediatrics · Revenue · Quarterly
$35M
Revenue by segment
OrthoPediatrics · $35M total across 3 segments · Q3 2022
- Trauma and Deformity$23.9M+42.1%68.4%
- Scoliosis$9.98M+37.3%28.5%
- Sports Medicine/Other$1.08M+8.3%3.1%
Forward guidance
For full year 2022, the Company now expects its full year revenue to be in the range of $124 million to $125 million, updated from its previous guidance range of $127 million to $130 million, representing growth of 26% to 27% over 2021 revenue.
Tailwinds
- Full year revenue expected to be in the range of $124 million to $125 million.
- Represents growth of 26% to 27% over 2021 revenue.
- Full year revenue, excluding recent acquisitions, expected to be in the range of $113 million to $114 million.
- Represents growth of 15% to 16% over 2021 revenue.
- Annual set deployment to be in a range of $20 million to $24 million.
Headwinds
- Previous revenue guidance range was $127 million to $130 million.
- Assumes roughly $11 million of combined revenue contribution from MD Ortho and Pega Medical.
- Pediatric orthopedic market faced additional headwinds beyond continued staffing shortages.
- RSV infections acutely impacted case volumes in certain regions
- No other negative guidance was provided
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.6%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+13.1%
Q2 2022
Best reaction
-13.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +13.7% | +14.0% | |
| Q4 2025 | +8.3% | +3.9% | -12.8% | |
| Q3 2025 | -2.6% | -3.0% | +9.3% | |
| Q1 2025 | +4.0% | +4.6% | -4.5% | |
| Q4 2024 | +11.9% | +7.0% | -0.8% | |
| Q3 2024 | -7.8% | -16.2% | -22.3% | |
| Q2 2024 | -7.8% | -9.0% | +3.8% | |
| Q1 2024 | +5.7% | -5.3% | -1.9% | |
| Q4 2023 | +5.4% | +1.9% | +0.8% | |
| Q3 2023 | +4.2% | -5.1% | +8.9% | |
| Q2 2023 | -4.6% | -4.9% | -7.2% | |
| Q1 2023 | -7.5% | -8.0% | -14.4% | |
| Q4 2022 | +0.5% | +1.7% | -0.8% | |
| Q3 2022 | -13.0% | -12.4% | +0.8% | |
| Q2 2022 | +13.1% | +19.2% | -0.8% | |
| Q1 2022 | -10.2% | -17.7% | -8.1% | |
| Q4 2021 | -5.8% | -6.3% | -2.0% | |
| Q3 2021 | +2.0% | +0.4% | -19.4% | |
| Q2 2021 | +6.9% | +4.5% | +9.2% | |
| Q1 2021 | +10.1% | +4.4% | +4.4% | |
| Q4 2020 | -7.1% | -8.6% | +2.3% | |
| Q3 2020 | -6.5% | +6.5% | -2.1% | |
| Q2 2020 | +4.7% | +9.7% | -0.6% | |
| Q1 2020 | +2.8% | +4.8% | +10.0% | |
| Q4 2019 | +1.1% | -4.5% | -19.5% | |
| Q3 2019 | +5.7% | +8.9% | +10.6% | |
| Q2 2019 | -0.2% | -1.0% | +10.9% | |
| Q1 2019 | -9.5% | -10.3% | -8.3% | |
| Q4 2018 | -4.3% | -2.0% | -6.2% | |
| Q3 2018 | -12.5% | -16.0% | -11.4% | |
| Q2 2018 | +2.7% | +2.7% | +23.7% | |
| Q1 2018 | -1.1% | +1.9% | +32.0% | |
| Q4 2017 | -1.9% | +3.4% | -2.9% | |
| Q3 2017 | -11.3% | -2.0% | -8.5% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro